PHILADELPHIA — In this exclusive video perspective from the American College of Gastroenterology Annual Meeting, Matt Mitcho, CEO of Gemelli Biotech, talks about the company’s new partnership with Cedars-Sinai, IBS Smart.
“We’re here at ACG to launch IBS Smart, a second-generation blood test to diagnose patients with IBS-D and IBS-M,” Mitcho told Healio Gastroenterology and Liver Disease. “IBS Smart looks at levels of anti-vinculin and anti-CDTB which are important biomarkers for patients with IBS.”
Mitcho said the partnership with the Medically Associated Science and Technology Program at Cedars Sinai Medical Center allows Gemelli to get a first look at cutting edge science that comes out of the program. IBS Smart is exclusively licensed by the MAST program to Gemelli.
Disclosure: Mitcho is employed by Gemelli.